Nuntius Therapeutics
About Nuntius Therapeutics
Nuntius Therapeutics develops programmable mRNA therapies using proprietary non-immunogenic nanocarriers that target a wide range of tissues and cell types, significantly enhancing delivery efficiency compared to existing technologies. The company focuses on treating life-threatening conditions such as cancer, lung diseases, and neurodegenerative disorders through superior nucleic acid engineering and machine learning-driven carrier selection.
```xml <problem> Current mRNA therapies face challenges in delivering genetic payloads to specific tissues and cell types, often resulting in limited efficacy and potential off-target effects. Existing delivery technologies struggle to efficiently target cells beyond the liver, hindering the development of mRNA-based treatments for a wide range of diseases. </problem> <solution> Nuntius Therapeutics develops programmable mRNA therapies using proprietary, non-immunogenic nanocarriers designed to enhance delivery efficiency to a wide range of tissues and cell types. The company leverages machine learning models to predict carrier quality and performance, guiding the selection of optimal candidates from a library of millions of distinct carriers. Nuntius also focuses on superior nucleic acid engineering to design mRNA with enhanced protein expression levels compared to existing mRNA therapeutics. This approach enables the development of transformative mRNA therapies for life-threatening conditions, including cancer, lung diseases, and neurodegenerative disorders. </solution> <features> - Proprietary nanocarriers for targeted delivery of mRNA to specific tissues and cell types - Non-immunogenic nanocarriers to minimize adverse immune responses - Machine learning models to predict carrier quality and performance - Superior nucleic acid engineering for enhanced protein expression levels - Scalable nanocarrier production for efficient manufacturing </features> <target_audience> The primary target audience includes pharmaceutical companies and research institutions focused on developing mRNA-based therapeutics for cancer, lung diseases, and neurodegenerative disorders. </target_audience> ```
What does Nuntius Therapeutics do?
Nuntius Therapeutics develops programmable mRNA therapies using proprietary non-immunogenic nanocarriers that target a wide range of tissues and cell types, significantly enhancing delivery efficiency compared to existing technologies. The company focuses on treating life-threatening conditions such as cancer, lung diseases, and neurodegenerative disorders through superior nucleic acid engineering and machine learning-driven carrier selection.
Where is Nuntius Therapeutics located?
Nuntius Therapeutics is based in London, United Kingdom.
When was Nuntius Therapeutics founded?
Nuntius Therapeutics was founded in 2021.
How much funding has Nuntius Therapeutics raised?
Nuntius Therapeutics has raised 125000.
- Location
- London, United Kingdom
- Founded
- 2021
- Funding
- 125000
- Employees
- 15 employees
- Major Investors
- Y Combinator, Eight Capital